MONTREAL, June 27, 2011 /CNW Telbec/ - Sunshine Biopharma Inc. (OTCBB
Ticker Symbol: SBFM) a development stage pharmaceutical company focused
on the research, development and commercialization of drugs for the
treatment of various forms of cancer, today announced that it has
completed a human microsome stability study of its lead compound,
Adva-27a targeted for aggressive types of cancer including multidrug
resistant breast cancer. The microsome stability test measures how
quickly the drug is eliminated by the body. Our results show that
Adva-27a has intermediate clearance time (half-life = 54 minutes)
similar to that of etoposide (half-life = 48 minutes) and other drugs
currently on the market.
"This is perfect, Adva-27a meets the criteria of a good pharmaceutical
drug", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "Rapid
clearance (i.e. short half-life) is undesirable as the drug would not
have enough time to act and slow clearance (i.e. long half-life) could
result in the drug being too toxic to administer", he added.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.
For further information:
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464